UNLABELLED: Pre-eclampsia is a complex disease with significant maternal and fetal morbidity and mortality. Its syndromic nature makes diagnosis and management difficult. The field is rapidly evolving with the definition of pre-eclampsia being challenged by some organisations, with proteinuria no longer being essential in the presence of other features. In the last decade, angiogenic factors, in particular soluble fms-like tyrosine kinase 1 (sFlt-1), have emerged as important molecules in the pathogenesis of pre-eclampsia. Here we review the most recent evidence regarding the potential of these factors as biomarkers and therapeutic targets for pre-eclampsia. TWEETABLE ABSTRACT: A review of angiogenic factors, sFlt-1 and PlGF, in the diagnosis, prediction and management of pre-eclampsia.
Journal article
2018-10-01T00:00:00+00:00
125
1389 - 1395
6
Angiogenic factors, National Institute for Clinical Excellence, fms-like tyrosine kinase 1, placental growth factor, pre-eclampsia, pregnancy, Angiogenesis Inducing Agents, Biomarkers, Female, Humans, Maternal Serum Screening Tests, Pre-Eclampsia, Pregnancy, Vascular Endothelial Growth Factor Receptor-1